The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

A new CT-scan-based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

Upstream Bio’s (NASDAQ:UPB – Get Free Report) lock-up period will end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size ...

The study results demonstrate the ability to improve the sense of smell with noninvasive devices in different types of users.

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Alvotech is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Charles Schwab Investment Management Inc. acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB – Free Report) during the 4th quarter, according to the company in its most recent Form ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...